arrow
A

Amy K. Keating

Harvard University
H指数:30
被引数:3,677

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL

异基因HSCT结局及defibrotide预防在inotuzumab治疗后儿童B-ALL患者中继发OS的影响

2026-07-200
OA
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults

采集时外周血 blasts 作为 tisagenlecleucel 治疗后儿童和年轻患者生存的风险因素

2026-01-010
OAAI
Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

放宽接受Tisagenlecleucel治疗的低负担B-ALL儿童/青年患者的医院邻近要求

2025-10-030
OAAI
Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant

整合肺和系统性转录组以表征儿童造血干细胞移植后的肺损伤

2025-09-090
OA
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel

儿科患者接受tisagenlecuecel治疗时血液毒性的表征与预测

2025-07-230
OAAI
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry

tisagenlecleucel 在复发/难治性B-ALL患者中的真实世界数据:来自CIBMTR登记研究的亚组分析

2025-06-260
OAAI
Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

B细胞恢复在复发风险和CD19表型中的作用:tisagenlecleucel用于儿童B淋巴细胞急性白血病真实世界应用的多机构回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation

接受干细胞移植的小儿患者的菌群失调肺损伤的病理生物学特征

2024-05-231
OAAI
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
2024-04-183
OAAI
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy

免疫重建分析表明,使用Omidubicel移植后具有抗病毒保护作用: 一项3期子研究

2023-08-016
OAAI
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL
2023-06-156
OAAI
Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients

在代表性不足的人群中获得嵌合抗原受体T细胞临床试验: 儿童和年轻成人急性淋巴细胞白血病患者的多中心队列研究

2023-06-0114
OAAI
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

异基因造血干细胞移植与omiudubicel的多中心长期随访: 五项前瞻性临床试验的汇总分析

2023-05-017
OAAI
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
2023-02-1729
OAAI
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

最佳氟达拉滨淋巴细胞耗竭与CAR T细胞治疗后结局改善相关

2022-03-2557
OAAI
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report

复发/难治性髓外ALL的Tisagenlecleucel结局: 儿科真实世界CAR联盟报告

2022-01-2141
OAAI